Pharmaceuticals

Amid massive layoffs and AI-driven shifts, the life sciences industry faces a structural crisis. Blue Matter's new practice offers a roadmap to survive.

With fresh funding secured, Dogwood Therapeutics pushes its promising nerve pain drug, Halneuron®, toward a pivotal data readout later this year.

With a major Series B financing, Crossbow advances its TCR-mimetic therapies, aiming to unlock a new frontier in the fight against a broad range of cancers.

Biotech firm ProMIS Neurosciences reveals novel vaccine data for ALS and Parkinson's, using a platform that selectively targets only toxic proteins.

Cingulate Inc. faces a critical FDA decision for its novel ADHD drug, but manufacturing queries and a tight cash runway create a high-stakes countdown.

Artelo Biosciences is testing a novel cannabinoid drug for glaucoma, aiming to protect vision in a way current treatments can't—all without diluting shares.

A new partnership will leverage genetically engineered mice to create novel antibody drugs, potentially unlocking treatments for cancer and brain diseases.

InflaRx announces a late-breaking presentation on its Phase 3 trial for vilobelimab, offering potential new hope for pyoderma gangrenosum patients.

ACTO's new AI suite automates workflows, promising to boost efficiency and compliance for pharma and medtech field professionals while keeping humans in control.

With a new CEO and Chair, IsomAb is advancing a disease-modifying drug for 9 million angina patients, eyeing a major Series A fundraise.

A new partnership seeks to conquer C. difficile, a deadly hospital infection that has stumped pharma giants, by advancing a novel dual-action vaccine.

New preclinical data reveals a novel gene therapy that not only kills tumor cells but also boosts immunity, offering hope against drug-resistant lung cancer.

A novel drug mimicking exercise aims to solve a major problem with today's weight-loss meds: muscle loss. Atrogi's ATR-258 has entered a key human trial.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

A new network for consumer ads is launching in 30,000 clinics, offering brands a trusted space but raising new questions about ethics and data privacy.

The deal, part of a broader consolidation strategy by parent The Lockwood Group, aims to meet rising pharma demand for advanced data and patient services.

With late-breaking hypertension data and an AI-driven platform, Kardigan is set to showcase a new, personalized approach to cardiovascular medicine.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

Consumers overcharged for generic drugs may get cash from a new $17.8M settlement. Find out if you're eligible and how this fits into a larger legal war.

Boston-based PhaseV unveils its AI Conductor, a new platform designed to automate the entire clinical trial lifecycle and accelerate FDA submissions.